Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating, and preventing, heart failure.
The newly discovered molecule provides the heart with a tool to block a protein that orchestrates genetic disruptions when the heart is subjected to stress, such as high blood pressure.
Researchers led by a team at Indiana University School of Medicine have discovered a cardiac compound that could lead to new treatment for heart failure.
Credit: Indiana University
When the research team, led by Ching-Pin Chang, M.D., Ph.D., associate professor of medicine at the Indiana University School of Medicine, restored levels of the newly discovered molecule in mice experiencing heart failure, the progression to heart failure was stopped. The research was published in the online edition of the journal Nature.
The newly discovered molecule is known as a long non-coding RNA. RNA's usual role is to carry instructions -- the code -- from the DNA in a cell's nucleus to the machinery in the cell that produces proteins necessary for cell activities. In recent years, scientists have discovered several types of RNA that are not involved in protein coding but act on their own. The role in the heart of long non-coding RNA has been unknown.
But the researchers determined that the newly discovered non-coding RNA, which they named Myheart -- for myosin heavy-chain-associated RNA transcript -- is responsible for controlling a protein called BRG1 (pronounced "berg-1"). In earlier research published in Nature in 2010, Dr. Chang and his colleagues discovered that BRG1 plays a crucial role in the development of the heart in the fetus.
But as the heart grows and needs to mature into its adult form, BRG1 is no longer needed, so very little of it is produced. That is, until the adult heart is subjected to significant stress such as high blood pressure or damage from a heart attack.
Dr. Chang's previous research showed that in those conditions, BRG1 re-emerges and begins altering the heart's genetic activity, leading to heart failure. At the same time, production of Myheart is suppressed, so BRG1 can latch onto the DNA and alter the genetic material unchecked.
In the current Nature paper, the researchers reported that in mice with stress-induced high levels of BRG1, they were able to restore Myheart to normal levels using gene transfer technology. Restoring Myheart levels blocked BRG1 actions and prevented heart failure, they said.
"I think of Myheart as a molecular crowbar that pries BRG1 off the genomic DNA and prevents it from manipulating genetic activity," said Dr. Chang, director of molecular and translational medicine at the Krannert Institute of Cardiology.
Although the results in mice would suggest testing Myheart against heart failure in humans, it is too large -- by molecular standards -- to be delivered as a drug, Dr. Chang said.
So he and his colleagues now are working to identify smaller portions of the Myheart molecule that are key to its ability to block BRG1. Such a subsection of the Myheart molecule could lead to a compound to test in human trials.
In addition to Dr. Chang and Pei Han, Ph.D., first author of the paper, investigators contributing to the research included Wei Li, Jin Yang and Peng-Sheng Chen of the IU School of Medicine; Chiou-Hong Lin, Ching Shang, Sylvia T. Nuernberg, Kevin Kai Jin, Weihong Xu, Chieh-Yu Lin, Chien-Jung Lin, Yiqin Xiong, Huan-Chieh Chien, Euan Ashley, Daniel Bernstein and Thomas Quertermous of the Stanford University School of Medicine; Bin Zhou of the Albert Einstein College of Medicine; and Huei-Sheng Vincent Chen of the Sanford/Burnham Medical Research Institute.
The research was supported by the American Heart Association (AHA; Established Investigator Award 12EIA8960018); the National Institutes of Health (NIH; HL118087, HL121197, HL109512, HL105194, HL78931, HL71140, HL116997, HL111770); California Institute of Regenerative Medicine (CIRM; RN2-00909, RB2-01512, RB4-06276); Stanford Heart Center Research Program; the IU School of Medicine-IU Health Strategic Research Initiative; the IU Physician-Scientist Initiative, endowed by Lilly Endowment; the Lucile Packard Foundation for Children's Health; the March of Dimes Foundation (#6-FY11-260); the Oak Foundation; and the Baxter Foundation.
Eric Schoch | Eurek Alert!
How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine
Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center
Physicists have developed a technique based on optical microscopy that can be used to create images of atoms on the nanoscale. In particular, the new method allows the imaging of quantum dots in a semiconductor chip. Together with colleagues from the University of Bochum, scientists from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute reported the findings in the journal Nature Photonics.
Microscopes allow us to see structures that are otherwise invisible to the human eye. However, conventional optical microscopes cannot be used to image...
On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.
We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
23.01.2018 | Earth Sciences
23.01.2018 | Life Sciences
23.01.2018 | Materials Sciences